Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer
Status:
Completed
Trial end date:
2015-12-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and activity of adding pazopanib to
weekly chemotherapy with paclitaxel for patients with ovarian cancer that is resistant or
refractory to treatment with platinum based therapy.